文献速递细菌感染、耐药与抗菌药物医院感染防控

抗感染活体生物治疗产品开发的机遇与挑战

Opportunities and Challenges in Development of Live Biotherapeutic Products to Fight Infections.
PubMed 文献 · J Infect Dis · 2021-01-01

本文综述了开发活体生物治疗产品(LBPs)用于控制多重耐药菌定植和感染的机遇与挑战。针对广谱抗生素破坏菌群导致耐药菌扩增的问题,LBPs可通过恢复肠道定植抵抗提供替代策略,但面临模型、剂量、生产、知识产权和商业可行性等挑战。

要点

  • 广谱抗生素破坏菌群控制耐药菌能力,LBPs可恢复定植抵抗。
  • LBPs开发聚焦粪菌移植类产品和明确细菌组合。
  • 面临候选选择模型、剂量、GMP、知识产权和商业可行性挑战。

核心结论

  • LBPs可恢复肠道定植抵抗、控制耐药菌扩增,是现有抗感染药物未满足的重要治疗需求。

研究设计与样本

  • 综述类文章,检索范围未明确报告。

主要发现

  • 广谱抗生素治疗细菌感染受限于扰动菌群控制耐药病原体扩增能力下降。
  • LBPs聚焦商业粪菌移植类产品和明确细菌组合。

临床怎么用

  • LBPs有望作为抗生素替代策略用于多重耐药菌定植和感染控制。

局限性

  • 开发面临候选选择模型、剂量方案、GMP、知识产权和商业可行性等挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of bacterial infections with broad-spectrum antibiotics is a strategy severely limited by the decreased ability of the perturbed resident microbiota to control expansion of antibiotic-resistant pathogens. Live biotherapeutic products (LBPs) could provide an alternative to antibiotics in infection control by restoring gut colonization resistance and controlling expansion of resistant strains, an important therapeutic need not being addressed with existing anti-infective drug modalities. We review opportunities and challenges in developing LBPs for multidrug-resistant organisms colonization and infection control, with a focus on commercial fecal microbiota transplantation-like products and defined bacterial consortia, and spanning considerations related to availability of models for rational drug candidate selection and dose regimen selection, good manufacturing practice, intellectual property, and commercial viability.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ducarmon QR, Kuijper EJ, Olle B, et al. Opportunities and Challenges in Development of Live Biotherapeutic Products to Fight Infections. J Infect Dis. 2021. PMID: 33576793. doi:10.1093/infdis/jiaa779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。